Company / Operating Income
PharmaCyte Biotech, Inc. Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$8.5M
FY2025
5-year range
-$8.5M / -$3.6M
FY2021-FY2025
Trend
-32.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Income has declined for 3 consecutive years, from -$4M in FY2022 to -$9M in FY2025.
Based on SEC 10-K filings.
-$9M in FY2025.
Declined from -$4M to -$9M over the past 2 years.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- PharmaCyte Biotech, Inc.'s operating income has declined for 3 consecutive years.
- In FY2025, operating income decreased 32.0% year-over-year.
- Peak operating income was recorded in FY2022.
- Lowest operating income in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score 0.20 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$8.5M | -32.0% |
| FY2024 | -$6.5M | -47.0% |
| FY2023 | -$4.4M | -21.2% |
| FY2022 | -$3.6M | +5.3% |
| FY2021 | -$3.8M | +6.7% |
| FY2020 | -$4.1M | +41.3% |
| FY2019 | -$7.0M | -57.2% |
| FY2018 | -$4.4M | +26.9% |
| FY2017 | -$6.1M | +68.0% |
| FY2016 | -$19.0M | -1026.8% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026